 |
(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Small cell lung cancer |
| USA Market Approval | USA |
| USA Designation Date | 2007-12-19 00:00:00 |
| Sponsor | AbbVie, Inc;1 North Waukegan Road, Dept. PA77, Bldg. AP30-1;North Chicago, Illinois, 60064 |
